REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com

REGENXBIO (NASDAQ:RGNX) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

A number of other research firms have also commented on RGNX. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday. Raymond James restated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Morgan Stanley restated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.82.

REGENXBIO Price Performance

Shares of REGENXBIO stock traded up $0.10 during trading on Thursday, hitting $7.95. 1,026,704 shares of the company’s stock traded hands, compared to its average volume of 1,321,670. The firm’s fifty day moving average price is $8.52 and its 200 day moving average price is $10.42. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The company has a market cap of $393.84 million, a PE ratio of -1.58 and a beta of 1.28.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors and hedge funds have recently modified their holdings of the business. Amalgamated Bank raised its stake in shares of REGENXBIO by 9.9% during the second quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,227 shares during the last quarter. FMR LLC grew its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC grew its holdings in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares during the period. GAMMA Investing LLC grew its holdings in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in REGENXBIO by 19.6% during the second quarter. The Manufacturers Life Insurance Company now owns 18,375 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 3,015 shares during the period. 88.08% of the stock is owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.